Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type The acquisition ensures continued access to this essential cholinesterase inhibitor for dementia patients in key markets Significant addition to Essential Pharma’s portfolio of specialty central nervous system (CNS) medicines and further expands the company’s presence globally Egham, UK – 17 April 2024 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.

Essential Pharma宣布收购Reminyl®（氢溴酸加兰他敏）口服胶囊Reminyl®是一个公认的中枢神经系统品牌，用于对阿尔茨海默病型轻度至中度重度痴呆症进行对症治疗。此次收购确保了痴呆症患者在关键市场上继续获得这种必需的胆碱酯酶抑制剂，这是Essential Pharma专业中枢神经系统（CNS）药物组合的重要补充，并进一步扩大了公司在英国埃格姆的全球业务。2024年4月17日，Essential Pharma是一家国际专业制药集团，专注于确保患者在关键治疗领域可持续获得低容量、临床差异化、利基制药产品，宣布已完成Reminyl®口服胶囊的收购来自强生公司Janssen Pharmaceutica NV。

Reminyl®, a cholinesterase inhibitor, is an established central nervous system (CNS) drug indicated for the treatment of mild to moderately severe dementia of the Alzheimer type. Under the terms of the acquisition, Essential Pharma has acquired rights to Reminyl® oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America.

Reminyl®是一种胆碱酯酶抑制剂，是一种已建立的中枢神经系统（CNS）药物，用于治疗阿尔茨海默病类型的轻度至中度严重痴呆。根据收购条款，Essential Pharma已在欧洲经济区、泰国、韩国和该产品的所有其他当前市场（不包括英国和爱尔兰、日本和拉丁美洲）收购了Reminyl®口服胶囊的权利。

The acquisition of Reminyl® represents further validation of Essential Pharma’s status as a trusted partner in ensuring the sustained supply of essential medicines to patients, healthcare providers and carers. As well as being an important addition to Essential Pharma’s portfolio of specialty CNS medicines, the acquisition further expands the Company’s presence globally, particularly in the APAC region.

Reminyl®的收购进一步验证了Essential Pharma作为可信赖合作伙伴的地位，以确保向患者、医疗保健提供者和护理人员持续供应基本药物。此次收购不仅是Essential Pharma专业中枢神经系统药物投资组合的重要补充，还进一步扩大了该公司在全球的业务范围，尤其是在亚太地区。

Emma Johnson, CEO of Essential Pharma, commented: “Our acquisition of rights to Reminyl® in these m.

Essential Pharma首席执行官艾玛·约翰逊（EmmaJohnson）评论道：“我们收购了这些m。